The report provides a detailed analysis essential for establishing an eliglustat tartrate production plant. It encompasses all critical aspects necessary for eliglustat tartrate production, including the cost of eliglustat tartrate production, eliglustat tartrate plant cost, eliglustat tartrate production costs, and the overall eliglustat tartrate production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an eliglustat tartrate production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Eliglustat Tartrate is a speciality pharmaceutical compound used mainly in the healthcare and pharmaceutical industry. It is primarily prescribed for the long-term treatment of adults with Gaucher disease type 1, a rare genetic disorder, by helping reduce the buildup of fatty substances in the body.
The compound works by slowing down the production of specific lipids (glyceramide), which helps manage symptoms and organ enlargement associated with the disease. It is also used as a first-line treatment in patients with rare lysosomal storage diseases characterised by the accumulation of lipid glucosylceramide (GL-1) due to insufficient production of the enzyme glucosylceramidase. It finds its major application in helping control symptoms like enlarged liver and spleen, bone pain, and low blood cell counts. It is mainly prescribed for patients who have a specific genetic profile that allows their body to process the drug safely. Moreover, it is also utilized in clinical research and drug development activities related to rare metabolic disorders.
The market for eliglustat tartrate is primarily driven by its demand as an oral agent for the treatment of Gaucher disease type 1 and lysosomal storage disorders in humans. Its application as an oral substrate reduction therapy for the treatment of type 1 Gaucher disease in adult patients significantly promotes its demand in the medical and pharmaceutical industries. Its usage as an alternative to enzyme replacement therapies for long-term disease management and improving the quality of life for affected individuals also promotes its demand in the healthcare sector.
Its demand for slowing down the production of a fatty substance called glucosylceramide, which reduces the burden on the body’s system responsible for breaking it down, also boosting its market growth. Industrial eliglustat tartrate procurement depends on factors such as the availability and cost of raw materials used in its synthesis, regulatory approvals in major markets, and the need for cold-chain-free logistics. Moreover, advancements in biotechnology, supplier consistency, and adherence to strict production and quality standards also play a vital role in shaping procurement practices globally.
Raw Material for Eliglustat Tartrate Production
According to the eliglustat tartrate production plant project report, the major raw materials for eliglustat tartrate production include S-(+)-2-phenyl glycinol, phenyl bromoacetate, pyrrolidine, palmitic acid Nhydroxysuccinimide (NHS)-ester, and tartaric acid.
Production Process of Eliglustat Tartrate
The extensive eliglustat tartrate production cost report consists of the following industrial production process:
- Production via Condensation: The production process of eliglustat tartrate begins with the condensation of S-(+)-2-phenyl glycinol and phenyl bromoacetate in the presence of DIPEA to form a morpholinone intermediate. This is then activated and reacted with a main aldehyde to construct the oxazine ring system with controlled stereochemistry. The oxazine intermediate is selectively opened using pyrrolidine to give an amide, which is further reduced to the corresponding amine. Then, the obtained amine undergoes hydrogenation, which removes the phenylethanol protecting group and forms the free amino alcohol, which is isolated as a stable dioxalate salt. Then, the amino alcohol is liberated under basic conditions and coupled with a palmitic acid Nhydroxysuccinimide (NHS)-ester to form eliglustat as the free base. Finally, the obtained compound is reacted with L-tartaric acid to facilitate the salt formation and produce eliglustat tartrate as the desired product.
Eliglustat Tartrate is the hemitartrate salt of eliglustat, and it acts as a potent and selective inhibitor of glucosylceramide synthase, which is an enzyme involved in glycosphingolipid biosynthesis. It appears as a white solid powder that is slightly soluble in DMSO and methanol but practically insoluble in water. The molecular formula of the compound is C50H78N4O14, and its molar mass is 959.17 g/mol. The compound decomposes at its melting point, which is above 133 °C. It should be stored at -20 °C under an inert atmosphere to maintain its stability. It is marketed under the brand name Cerdelga. The flash point of the compound is around 14 °C, and it is generally stored at -20 °C. The compound should be handled with care, and appropriate protective measures should be followed during handling, as it is intended strictly for therapeutic use under medical supervision.